News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Eyetech Pharmaceuticals Will Be Closely Watched
October 19, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
In the sagging market for biotechnology-company IPOs, all eyes are on Eyetech Pharmaceuticals Inc.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Insights
Programmable RNA 2.0: Beyond the First mRNA Revolution
February 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
Pfizer’s Metsera Data, 2025 Earnings, the FDA and REGENXBIO, Psychedelics and IPOs
February 4, 2026
·
1 min read
·
Heather McKenzie
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
February 4, 2026
·
11 min read
·
Tristan Manalac
Deals
Roche Keeps the Deals Coming With up to $1.7B SangeneBio RNAi Pact
February 3, 2026
·
1 min read
·
Tristan Manalac
